Fachrepositorium Lebenswissenschaften

7 Treffer

Suche

Publisso-Menue

Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Case-Control Study

2024 . Lee, John JW. | Alamleh, Salahaldin | Zhan, Luna Jia | Hueniken, Katrina | Mahler, Mary B. | Billfalk-Kelly, Astrid | Davies, Joel | Brown, M. Catherine | Spreafico, Anna | Huang, Shao Hui | Hope, Andrew | Xu, Wei | Goldstein, David P. | Liu, Geoffrey

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial

2021 . Pöttgen, Christoph | Gkika, E. | Stahl, M. | Abu Jawad, J. | Gauler, T. | Kasper, S. | Trarbach, T. | Herrmann, K. | Lehmann, N. | Jöckel, K.-H. | Lax, H. | Stuschke, M.

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

2021 . Taugner, Julian | Käsmann, Lukas | Karin, Monika | Eze, Chukwuka | Flörsch, Benedikt | Guggenberger, Julian | Li, Minglun | Tufman, Amanda | Reinmuth, Niels | Duell, Thomas | Belka, Claus | Manapov, Farkhad

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

2020 . Bozorgmehr, Farastuk | Chung, Inn | Christopoulos, Petros | Krisam, Johannes | Schneider, Marc A. | Brückner, Lena | Mueller, Daniel Wilhelm | Thomas, Michael | Rieken, Stefan

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)